Wire Stories
-
687Draganfly Signs $9 Million Exclusive Manufacturing Agreement with Digital Dream Labs
Los Angeles, CA., Oct. 12, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (�Draganfly� or the �Company�), an...
-
544Gilat to Report Third Quarter 2021 Results on November 9th �
PETAH TIKVA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking...
-
738Canva Launches Video Suite to Empower Everyone to Create, Edit and Record Stunning Videos
68% of U.S. knowledge workers say video is becoming increasingly important in the workplace SYDNEY–(BUSINESS WIRE)–Canva, the visual communications platform, today launched...
-
540
VIQ Solutions Announces Agreement to Acquire Assets of Court Recording and Transcription Services Company Auscript Australasia Pty Ltd
PHOENIX, Ariz.–(BUSINESS WIRE)–VIQ Solutions Inc. (�VIQ� or the �Company�) (TSX and Nasdaq: VQS), a global provider of secure, AI-driven, digital voice and...
-
548
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV� (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., �Astellas�) today announced that...
-
750
Xperi Licenses Hybrid Bonding Technology to Yangtze Memory Technologies Co., Ltd. (YMTC)
Direct Bond Interconnect (DBI�) hybrid bonding portfolio licensed to YMTC for its 3D NAND memory products SAN JOSE, Calif.–(BUSINESS WIRE)–Xperi Holding Corporation�...
-
619
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR� mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
– Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants – Initiation of Phase 3b study follows review...
-
700
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical...
-
576
China & International Automotive Infrared Night Vision System Markets Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Automotive Infrared Night Vision System Research Report, 2021” report has been added to ResearchAndMarkets.com’s offering. This report combs through development...
-
623
Apromore Joins Forces with UltimateSuite to Combine Best-of-Breed Process Mining and Task Mining Capabilities
Enterprises now have a best-of-breed pathway to extract high-fidelity insights into their end-to-end business processes MELBOURNE, Australia & PRAGUE, Czech Republic–(BUSINESS WIRE)–Apromore,...
